Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. reports developments in AI-enabled personalized spine surgery solutions for lumbar and cervical procedures. The company designs, manufactures and markets the aprevo® technology platform, which combines customized surgical planning with patient-specific implants for spine fusion procedures sold primarily to hospitals and ambulatory surgical centers.
Carlsmed news commonly covers quarterly financial results, revenue guidance, clinical data for aprevo® personalized implants, product updates for cervical and patient-specific fixation systems such as corra™, and management presentations at healthcare and medical technology investor conferences.
Carlsmed (NASDAQ: CARL) reported Q1 2026 results: $16.1M revenue (58% YoY), $12.4M gross profit, gross margin 77.1%, and net loss of $8.7M. Adjusted EBITDA was -$7.5M. Cash and equivalents totaled $97.1M. Full-year 2026 revenue guidance raised to $72–$77M from $70–$75M.
Clinical progress includes a published study showing a 74% reduction in reoperations for aprevo and early procedures for corra and aprevo bi-lateral posterior.
Carlsmed (Nasdaq: CARL) announced CEO Mike Cordonnier will participate in multiple investor conferences in May–June 2026, including Bank of America Global Healthcare (May 12), Jefferies Global Healthcare (June 4), Goldman Sachs Global Healthcare (June 10) and Truist MedTech (June 16).
Live webcasts will be available for scheduled fireside chats and archived on the company’s Events and Presentations page at investors.carlsmed.com; management will hold one-on-one meetings on select dates.
Carlsmed (Nasdaq: CARL) will report first quarter 2026 results after market close on Tuesday, May 5, 2026. Management will host a conference call and concurrent webcast at 1:30 PM Pacific Time with a replay available shortly after and archived on the company website.
Participant registration is required via the provided registration link; callers should dial in 5–10 minutes before the start time.
Carlsmed (Nasdaq: CARL) announced that CEO and Chairman Mike Cordonnier will present at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET.
A live webcast will be available to registered participants, and a replay will be posted after the presentation.
Carlsmed (Nasdaq: CARL) reported strong revenue growth with Q4 2025 revenue $15.2M (+61% YoY) and full-year 2025 revenue $50.5M (+86% YoY). Gross margin expanded to 75.3% for 2025 and cash resources were $109.9M at year-end. Management provided 2026 revenue guidance of $70–$75M.
Company highlighted published 2-year aprevo lumbar outcomes showing a 74% reduction in revision rates and multiple product and first-in-human procedural milestones in February 2026.
Carlsmed (Nasdaq: CARL) said CEO and Chairman Mike Cordonnier will present at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans. A live webcast is available to registered participants and a replay will be posted afterward.
Carlsmed (Nasdaq: CARL) announced the first personalized cervical plating procedure using the corra™ Cervical Plating System on Feb. 18, 2026.
The procedure, performed by Dr. Aaron Clark at UCSF, begins a clinical evaluation ahead of a planned commercial launch of corra™ later in 2026 and highlights integration with aprevo® planning and interbody devices.
Carlsmed (Nasdaq: CARL) will report fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will host a conference call and concurrent webcast at 1:30 PM Pacific Time, with a replay archived on the company's website.
Carlsmed (Nasdaq: CARL) announced the first posterior lumbar spine surgery using its aprevo® Lumbar Bi-lateral Posterior System, performed Feb. 10, 2026 at University of Colorado Hospital.
The company says the procedure demonstrates aprevo® integration across lumbar fusion approaches and expects a full commercial launch later in 2026.
Carlsmed (Nasdaq: CARL) reported preliminary unaudited revenue of approximately $15.2 million for the fourth quarter of 2025, about +61% versus Q4 2024, and preliminary full year 2025 revenue of approximately $50.5 million, about +86% versus 2024. The company said it added 101 new surgeon users in 2025, a 61% increase in its surgeon user base, and launched aprevo cervical with early positive surgeon feedback. Results are preliminary, unaudited and subject to revision until the Company files its 2025 Annual Report on Form 10-K.